Research interests

The targeted drug development group at the department of Oncogenomics aims at the identification and validation of new therapeutic interventions for pediatric neuroblastoma. A highly efficient pipeline covering the full spectrum of targeted drug development is currently functional. The process starts with the identification of new drug targets using high throughput analysis as Affymetrix mRNA profiling, aCGH, MIR profiling and recently also Whole Genome Sequencing. Potential new target genes are subsequently validated in neuroblastoma cell line systems using a variety of molecular genetic manipulation techniques. The most promising target genes are then inhibited using small molecule inhibitors in vitro and in vivo. Several new models are developed to consolidate this process. Tumor Initiating Cell lines are isolated from patient material to obtain representative tumor systems and new xenograft models are developed.
 

specialisation

Targeted drug development

ID: 74182